University Of Queensland Glycochemistry News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from University of queensland glycochemistry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In University Of Queensland Glycochemistry Today - Breaking & Trending Today

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2
QUT PhD researcher Zachariah Schuurs said the research team had identified a new binding site on the SARS-CoV-2 spike protein.
Binding of the CoV-2 spike protein to heparan sulphate (HS) on cell surfaces is generally the first step in a cascade of interactions the virus needs to initiate an infection and enter the cell.
Most research has focused on understanding how HS interacts on the receptor-binding domain (RBD) and furin cleavage site of the SARS-CoV-2 virus s spike protein, as these typically bind different types of drugs, vaccines and antibodies.
We have identified a novel binding site on the N-terminal domain (NTD), a different area of the virus s spike that facilitates the binding of HS. This helps to better understand how the virus infects cells. The NTD is also a part of the spike protein that frequently mutates. ....

South Africa , Zachariah Schuurs , Sneha Gandhi , Emily Henderson , University Of Queensland Glycochemistry , Personalised Health , Centre For Genomics , Zucero Pharmaceuticals , Curtin University Immunology , Structural Biotechnology Journal , Curtin University , நேஹா காந்தி , எமிலி ஹென்டர்சன் , தனிப்பயனாக்கப்பட்டது ஆரோக்கியம் , மையம் க்கு மரபியல் , கட்டமைப்பு உயிரி தொழில்நுட்பவியல் இதழ் , கர்டின் பல்கலைக்கழகம் ,

Anti-coagulant drug could treat COVID-19's emerging variants

Date Time
Anti-coagulant drug could treat COVID-19’s emerging variants
Molecules from the same family as the anti-coagulant drug heparin may interfere with the ability of the COVID-19 virus’s spikes to bind to human cells. This could be used to treat people with severe effects of the virus and any emerging variants.
New targetable site on the COVID-19 spike protein discovered
Heparin-like molecules, a common anti-coagulant, could prevent the virus from infecting cells
Low vaccine coverage in many countries means more vaccine-resistant mutations likely to appear.
QUT PhD researcher Zachariah Schuurs said the research team had identified a new binding site on the SARS-CoV-2 spike protein. ....

South Africa , United Kingdom , Zachariah Schuurs , Sneha Gandhi , University Of Queensland Glycochemistry , National Institute For Biological Standards , Collaborators At University Of Liverpool , Keele University , Personalised Health , Centre For Genomics , Zucero Pharmaceuticals , Curtin University Immunology , Structural Biotechnology Journal , Curtin University , National Institute , Biological Standards , Ricerche Chimiche , ஒன்றுபட்டது கிஂக்டம் , நேஹா காந்தி , தேசிய நிறுவனம் க்கு உயிரியல் தரநிலைகள் , கீல் பல்கலைக்கழகம் , தனிப்பயனாக்கப்பட்டது ஆரோக்கியம் , மையம் க்கு மரபியல் , கட்டமைப்பு உயிரி தொழில்நுட்பவியல் இதழ் , கர்டின் பல்கலைக்கழகம் , தேசிய நிறுவனம் ,